Alto Neuroscience, Inc.
ANRO
$27.04
$1.746.88%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 20.03% | -18.36% | -24.03% | 7.78% | 28.60% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 73.12% | 0.34% | -20.84% | 1.86% | 8.97% |
| Operating Income | -73.12% | -0.34% | 20.84% | -1.86% | -8.97% |
| Income Before Tax | -72.96% | -6.45% | 15.50% | -10.46% | -13.06% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -72.96% | -6.45% | 15.50% | -10.46% | -13.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -72.96% | -6.45% | 15.50% | -10.46% | -13.06% |
| EBIT | -73.12% | -0.34% | 20.84% | -1.86% | -8.97% |
| EBITDA | -73.84% | -0.42% | 21.19% | -1.56% | -8.51% |
| EPS Basic | -42.23% | 16.63% | 15.95% | -9.81% | 26.43% |
| Normalized Basic EPS | -48.89% | 16.60% | 15.96% | -9.80% | 29.74% |
| EPS Diluted | -42.23% | 16.63% | 15.95% | -9.81% | 26.43% |
| Normalized Diluted EPS | -48.89% | 16.60% | 15.96% | -9.80% | 29.74% |
| Average Basic Shares Outstanding | 21.61% | 27.67% | 0.54% | 0.59% | 53.69% |
| Average Diluted Shares Outstanding | 21.61% | 27.67% | 0.54% | 0.59% | 53.69% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |